Gabafast

Gabafast

gabapentin

Manufacturer:

Kusum

Distributor:

JDS
Concise Prescribing Info
Contents
Gabapentin
Indications/Uses
Adjunctive therapy in partial seizures w/ & w/o secondary generalization in adults & childn ≥6 yr. Monotherapy in partial seizures w/ & w/o secondary generalization in adults & adolescents ≥12 yr. Peripheral neuropathic pain eg, painful diabetic neuropathy & post-herpetic neuralgia in adults.
Dosage/Direction for Use
Epilepsy Adult & adolescent Initially, 300 mg tds on day 1. May be further increased in 300 mg daily increments every 2-3 days up to max 3,600 mg daily based on individual patient response & tolerability. Childn ≥6 yr Initially 10-15 mg/kg daily, up-titrated over approx 3 days to reach effective dose of 25-35 mg/kg daily. Total daily dose should be divided in 3 single doses & max time interval between doses should not exceed 12 hr. Peripheral neuropathic pain Adult Initially 900 mg daily given as 3 equally divided doses. May be further increased in 300 mg daily increments every 2-3 days up to max 3,600 mg daily based on individual patient response & tolerability. Renal impairment CrCl ≥80 mL/min 900-3,600 mg daily, 50-79 mL/min 600-1,800 mg daily, 30-49 mL/min 300-900 mg daily, 15-29 mL/min 150-600 mg daily, <15 mL/min 150-300 mg daily. Total daily doses should be administered as 3 divided doses. Patients undergoing haemodialysis Loading dose: 300-400 mg, then 200-300 mg following each 4-hr haemodialysis.
Administration
May be taken with or without food: Swallow whole w/ sufficient fluid (eg, a glass of water).
Contraindications
Special Precautions
Discontinue if acute pancreatitis develops. Not effective against primary generalized seizures eg, absences. Abrupt withdrawal may precipitate status epilepticus in epileptic patients. Monitor for signs or suicidal ideation & behaviours, CNS & resp depression. Evaluate patients for history of drug abuse & early manifestations of hypersensitivity eg, fever or lymphadenopathy. False positive readings in semi-quantitative determination of total urine protein by dipstick tests. May influence ability to drive & use machines. Not to be used during pregnancy. Lactation. Prolonged therapy in childn & adolescents. Elderly >65 yr.
Adverse Reactions
Viral infection; somnolence, dizziness, ataxia; fatigue, fever. Pneumonia, resp infection, UTI, infection, otitis media; leucopenia; anorexia, increased appetite; hostility, confusion & emotional lability, depression, anxiety, nervousness, abnormal thinking; convulsions, hyperkinesias, dysarthria, amnesia, tremor, insomnia, headache, sensations, abnormal coordination, nystagmus, increased, decreased, or absent reflexes; visual disturbances; vertigo; HTN, vasodilatation; dyspnoea, bronchitis, pharyngitis, cough, rhinitis; vomiting, nausea, dental abnormalities, gingivitis, diarrhoea, abdominal pain, dyspepsia, constipation, dry mouth or throat, flatulence; facial oedema, purpura, rash, pruritus, acne; arthralgia, myalgia, back pain, twitching; impotence; peripheral oedema, abnormal gait, asthenia, pain, malaise, flu syndrome; decreased WBC, wt gain; accidental injury, fracture, abrasion.
Drug Interactions
Resp depression &/or sedation w/ opioids. Reduced bioavailability w/ antacids containing Al & Mg.
MIMS Class
Anticonvulsants
ATC Classification
N03AX12 - gabapentin ; Belongs to the class of other antiepileptics.
Presentation/Packing
Form
Gabafast 300 mg cap
Packing/Price
10 × 10's;3 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in